On the origins of clinical drug resistance.
Recent progress in understanding the clinical importance of certain laboratory models of drug resistance is cause for clinical oncologists to rethink some of the current concepts used in developing chemotherapy programs. The following discussion will reexamine a popular model of resistance development and highlight certain insights gained from clinical and laboratory studies of multidrug resistance. Such insights both challenge traditional concepts of cancer treatment and suggest new therapeutic approaches that would otherwise not have been apparent.
Department of Medicine, Sloan-Kettering Cancer Center, New York.
J P
JP
O'Brien
C
C
Cordon-Cardo
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D004351:Drug Resistance / Q000235:genetics / Q000502:physiology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000502:physiology; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D008562:Membrane Glycoproteins